The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a more substantial decrease in body mass and improve metabolic health, particu